Tradestie Institutional Equity Comparison Engine
ICCC vs SRZN โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ICCC Overall Edge
ICCC Captures Institutional Edge (2โ2 Pillars ยท 7โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Immucell Corp (ICCC) driven by superior Valuation, Growth & Margin while SRZN counters with relative strength in Momentum & Technical, Options & Structure. Fundamentally, ICCC trades at N/M Forward P/E with 15.2% operating margin (+11.5% YoY revenue) versus SRZN at N/M Forward P/E and -485.4% operating margin (+408.6% YoY). In options structure, ICCC sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against SRZN sits in CONSOLIDATION (5th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
ICCC
ICCC N/M vs SRZN N/M Fwd P/E
Growth & Margin Winner
ICCC
Op Margin 15.2% vs -485.4% ยท YoY +11.5% vs +408.6%
Momentum & Technical Winner
SRZN
1Y +88.8% vs +166.7% ยท 52W Pos 91% vs 79%
Options & Structure Winner
SRZN
UNCLASSIFIED (N/A IV) vs CONSOLIDATION (5th %ile IV)
ICCC
NASDAQ
Immucell Corp
In Vitro & In Vivo Diagnostic Substances
$11.42
+6.23% 1D
Market Cap
$97.7M
1M Return
+6.23%
1Y Return
+88.76%
Forward P/E
N/M
Unified AI Score
43.8 / 100
HOLD
Tech 15.0
Fund 48.0
Flow 50.0
Mom 50.0
SRZN
NASDAQ
Surrozen, Inc. Common
Biological Products, (No Disgnostic Substances)
$32.32
+2.25% 1D
Market Cap
$602.5M
1M Return
+37.88%
1Y Return
+166.67%
Forward P/E
N/M
Unified AI Score
34.3 / 100
SELL
Tech 5.0
Fund 32.0
Flow 65.0
Mom 40.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
ICCC +88.76%
SRZN +166.67%
Spread: +77.91 pp (SRZN Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | ICCC Revenue | SRZN Revenue | ICCC Op. Margin | SRZN Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $10M | N/A | -13.2% | N/A | ICCC |
| FY2019 | $10M | N/A | -7.0% | N/A | ICCC |
| FY2020 | $20M | N/A | -9.0% | N/A | ICCC |
| FY2021 | $20M | N/A | 1.3% | N/A | ICCC |
| FY2022 | $20M | $10M | -12.4% | -354.7% | ICCC |
| FY2023 | $20M | N/A | -32.9% | N/A | ICCC |
| FY2024 | $30M | $10M | -6.2% | -239.7% | ICCC |
| FY2025 | $30M | $0M | 6.0% | -1210.6% | ICCC |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | ICCC | SRZN | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $97.7M | $602.5M | Larger Scale | SRZN |
| Trailing P/E Ratio Valuation | 56.6x | N/M | Lower Multiple | ICCC |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +11.5% | +408.6% | Higher Growth | SRZN |
| Operating Margin (TTM) Profitability | 15.2% | -485.4% | Higher Margin | ICCC |
| Net Profit Margin Profitability | 2.6% | 0.0% | Higher Margin | ICCC |
| Return on Equity (ROE) Capital Efficiency | 2.6% | -62.8% | Higher ROE | ICCC |
| 52-Week Range Position Momentum | 91% ($5โ$12) | 79% ($12โ$38) | Stronger Trend | ICCC |
| Beta / 30D Volatility Risk Regime | 0.24ฮฒ ยท 46% Vol | 1.21ฮฒ ยท 62% Vol | Lower Realized Risk | ICCC |
| Unified Institutional Score Composite Signal | 43.8 / 100 (HOLD) | 34.3 / 100 (SELL) | Higher Composite | ICCC |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full ICCC vs SRZN Buy Guide
ICCC
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
SRZN
CONSOLIDATION
37d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
5th %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither ICCC nor SRZN registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.